Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $3.70M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Lisata Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −2 vs. Q1 2025
- Shares held
- 782.5K
- −867 (−0.1%) vs. Q1 2025
- Total value
- $2.26M
- +$416.8K (+22.6%) vs. Q1 2025
- New holders
- 2
- 5 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LSTA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $3.70M |
| Q1 2026 | 34 | $7.06M |
| Q4 2025 | 25 | $1.36M |
| Q3 2025 | 21 | $1.93M |
| Q2 2025 | 20 | $2.26M |
| Q1 2025 | 22 | $1.84M |
| Q4 2024 | 21 | $2.33M |
| Q3 2024 | 20 | $2.30M |
| Q2 2024 | 22 | $2.61M |
| Q1 2024 | 21 | $2.30M |
| Q4 2023 | 22 | $2.03M |
| Q3 2023 | 21 | $1.46M |
| Q2 2023 | 22 | $2.51M |
| Q1 2023 | 21 | $2.08M |
| Q4 2022 | 24 | $1.83M |
| Q3 2022 | 22 | $2.17M |
| Q2 2022 | 36 | $5.00M |
| Q1 2022 | 34 | $6.13M |
| Q4 2021 | 36 | $7.33M |
| Q3 2021 | 34 | $9.41M |
| Q2 2021 | 29 | $10.1M |
| Q1 2021 | 33 | $12.9M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Lisata Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cheviot Value Management, LLC | 3 | $8 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 4 | $12 | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 6 | $17 | 0.00% | +6 | New |
| SBI Securities Co., Ltd. | 140 | $406 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 224 | $649 | 0.00% | −1,242−84.7% | Reduced |
| Tower Research Capital LLC (TRC) | 1,323 | $3.84K | 0.00% | −884−40.1% | Reduced |
| Founders Capital Management | 2,000 | $5.80K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 5,912 | $17.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 7,069 | $20.5K | 0.00% | +7,068+706,800.0% | Added |
| HighTower Advisors, LLC | 10,042 | $29.1K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 10,268 | $29.8K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 10,421 | $30.2K | 0.00% | +8+0.1% | Added |
| Cerity Partners LLC | 12,183 | $32.3K | 0.00% | +12,183 | New |
| State Street Corp | 14,348 | $41.3K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 25,793 | $74.3K | 0.00% | +571+2.3% | Added |
| BlackRock, Inc. | 54,857 | $159.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 61,082 | $176.0K | 0.00% | +553+0.9% | Added |
| Renaissance Technologies LLC | 102,822 | $298.1K | 0.00% | +100+0.1% | Added |
| BML Capital Management, LLC | 209,814 | $608.3K | 0.47% | −7,039−3.2% | Reduced |
| Vanguard Group Inc | 254,182 | $732.0K | 0.00% | 00.0% | Unchanged |
| Cook Wealth Management Group LLC | 0 | $0 | 0.00% | −12,175−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Loring Wolcott & Coolidge Fiduciary Advisors LLP | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −1−100.0% | Sold out |